These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors. Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992 [TBL] [Abstract][Full Text] [Related]
5. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2. Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545 [TBL] [Abstract][Full Text] [Related]
6. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents. Gangjee A; Adair OO; Queener SF J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957 [TBL] [Abstract][Full Text] [Related]
8. 4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4). Tsou HR; Otteng M; Tran T; Floyd MB; Reich M; Birnberg G; Kutterer K; Ayral-Kaloustian S; Ravi M; Nilakantan R; Grillo M; McGinnis JP; Rabindran SK J Med Chem; 2008 Jun; 51(12):3507-25. PubMed ID: 18494457 [TBL] [Abstract][Full Text] [Related]
9. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. Park H; Yeom MS; Lee S Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811 [TBL] [Abstract][Full Text] [Related]
10. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity. Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073 [TBL] [Abstract][Full Text] [Related]
11. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. Zhu G; Conner SE; Zhou X; Shih C; Li T; Anderson BD; Brooks HB; Campbell RM; Considine E; Dempsey JA; Faul MM; Ogg C; Patel B; Schultz RM; Spencer CD; Teicher B; Watkins SA J Med Chem; 2003 May; 46(11):2027-30. PubMed ID: 12747775 [TBL] [Abstract][Full Text] [Related]
14. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031 [TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932 [TBL] [Abstract][Full Text] [Related]
16. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371 [TBL] [Abstract][Full Text] [Related]
17. Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). Reddy MV; Akula B; Cosenza SC; Athuluridivakar S; Mallireddigari MR; Pallela VR; Billa VK; Subbaiah DR; Bharathi EV; Vasquez-Del Carpio R; Padgaonkar A; Baker SJ; Reddy EP J Med Chem; 2014 Feb; 57(3):578-99. PubMed ID: 24417566 [TBL] [Abstract][Full Text] [Related]
18. Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold. Elzahabi HSA; Nossier ES; Khalifa NM; Alasfoury RA; El-Manawaty MA J Enzyme Inhib Med Chem; 2018 Dec; 33(1):546-557. PubMed ID: 29482389 [TBL] [Abstract][Full Text] [Related]